Form 4: Arcturus Therapeutics CFO Acquires Stock Options

Arcturus Therapeutics Holdings Inc. reports that Chief Financial Officer Dennis Mulroy acquired 100,000 employee stock options.

Summary

• Dennis Mulroy, Chief Financial Officer of Arcturus Therapeutics Holdings Inc., was granted 100,000 employee stock options.
• The options have an exercise price of $8.63 and were granted on May 1, 2026.
• These options vest over a period of four years, with 25% vesting on May 1, 2027, and the remainder vesting monthly thereafter.
• The underlying securities are 100,000 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard executive stock option grant without immediate financial impact or significant strategic news.

Positives

• Grant of significant stock options to the Chief Financial Officer, indicating potential alignment of management incentives with company performance.
• The exercise price of $8.63 suggests a potential for future stock appreciation if the company's value increases.

Risks

• The value of the stock options is contingent on the future performance of Arcturus Therapeutics Holdings Inc. and its stock price.
• Vesting schedules mean that the full benefit of the options is not realized immediately, requiring continued service and company success.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The future outlook for the stock options depends entirely on the company's future stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to key executives is a common practice in the biotechnology and pharmaceutical sectors to incentivize performance and retain talent, especially in companies focused on research and development where long-term success is critical.

Stakeholder Impact

• Shareholders: The grant of options does not immediately dilute share count but represents potential future dilution if exercised. It can be seen as a positive alignment of management interests.
• Employees: May signal a positive outlook for the company, potentially boosting morale.
• Management: Directly benefits from the potential appreciation of the company's stock price.

Next Steps

• The options will vest over a four-year period, starting May 1, 2027.
• The reporting person may exercise the vested options at any time up to the expiration date of May 1, 2036.

Key Dates

Keywords

Arcturus Therapeutics, ARCT, Form 4, Stock Options, Employee Stock Option, Dennis Mulroy, CFO, SEC Filing, Beneficial Ownership